Carlos Galera

875 total citations
18 papers, 252 citations indexed

About

Carlos Galera is a scholar working on Infectious Diseases, Virology and Emergency Medicine. According to data from OpenAlex, Carlos Galera has authored 18 papers receiving a total of 252 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Infectious Diseases, 8 papers in Virology and 6 papers in Emergency Medicine. Recurrent topics in Carlos Galera's work include HIV Research and Treatment (8 papers), HIV-related health complications and treatments (6 papers) and HIV/AIDS drug development and treatment (6 papers). Carlos Galera is often cited by papers focused on HIV Research and Treatment (8 papers), HIV-related health complications and treatments (6 papers) and HIV/AIDS drug development and treatment (6 papers). Carlos Galera collaborates with scholars based in Spain, United States and United Kingdom. Carlos Galera's co-authors include Félix Gutiérrez, Vicente Boix, Esperanza Merino, C Redondo, José López‐Aldeguer, Brian Wynne, Jean van Wyk, Laurent Hocqueloux, J Oyee and Sergio Padilla and has published in prestigious journals such as Clinical Infectious Diseases, Scientific Reports and Frontiers in Immunology.

In The Last Decade

Carlos Galera

18 papers receiving 244 citations

Peers

Countries citing papers authored by Carlos Galera

Since Specialization

Citations

This map shows the geographic impact of Carlos Galera's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carlos Galera with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carlos Galera more than expected).

Fields of papers citing papers by Carlos Galera

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carlos Galera. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carlos Galera. The network helps show where Carlos Galera may publish in the future.

Co-authorship network of co-authors of Carlos Galera

This figure shows the co-authorship network connecting the top 25 collaborators of Carlos Galera. A scholar is included among the top collaborators of Carlos Galera based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carlos Galera. Carlos Galera is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	Real-life data of immune recovery using bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people living with HIV. Results at 48–96 weeks of RETROBIC Study 2024 ·Journal of Antimicrobial Chemotherapy ·Jesús Troya, (unknown), (unknown), Carlos Galera, José Sanz, Ignacio de los Santos, Carlos Dueñas, Noemí Cabello, (unknown), (unknown), María Ángeles Garcinuño, (unknown), Luís Buzón	4
2	IP-10 and MIG are sensitive markers of early virological response to HIV-1 integrase inhibitors 2023 ·Frontiers in Immunology ·(unknown), Alicia Gutiérrez‐Valencia, Ana Mariño, (unknown), (unknown), Alexandre Pérez‐González, (unknown), (unknown), (unknown), Santiago Moreno, Teresa Aldámiz, Marta Montero, Enrique Bernal, Carlos Galera, Josep M. Llibre, Eva Poveda	4
3	Response to glecaprevir/pibrentasvir in HIV/HCV-coinfected patients in clinical practice 2023 ·Journal of Antimicrobial Chemotherapy ·Alejandro González‐Serna, Anaïs Corma‐Gómez, Francisco Téllez, (unknown), Maria José Ríos-Villegas, Dolores Merino, Carlos Galera, Antonio Collado, Ignacio de los Santos, (unknown), Marta Santos, (unknown), Antonio Rivero, Luís Miguel Real, Juan Macı́as	4
4	Long-Term Changes of Inflammatory Biomarkers in Individuals on Suppressive Three-Drug or Two-Drug Antiretroviral Regimens 2022 ·Frontiers in Immunology ·Sergio Serrano‐Villar, María Rosa López‐Huertas, (unknown), Carlos Galera, Javier Martínez‐Sanz, Elena Moreno, Alfonso Muriel, Félix Gutiérrez, Carmen Busca, Joaquín Portilla, Otilia Bisbal, José Antonio Iribarren, Francisco Tejerina, Ignacio de los Santos, Santiago Moreno	6
5	Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial 2022 ·Clinical Infectious Diseases ·Josep M. Llibre, Carlos Brites, Chien‐Yu Cheng, Olayemi Osiyemi, Carlos Galera, Laurent Hocqueloux, Franco Maggiolo, Olaf Degen, Stephen Taylor, Elizabeth A. Blair, Choy Man, Brian Wynne, J Oyee, Mark Underwood, Lloyd Curtis, (unknown), Jean van Wyk	80
6	A Genome-Wide Association Study on Liver Stiffness Changes during Hepatitis C Virus Infection Cure 2021 ·Diagnostics ·Anaïs Corma‐Gómez, Juan Macı́as, Antonio Rivero, Antonio Rivero‐Juárez, Ignacio de los Santos, Sergio Reus, Luís Morano, Dolores Merino, Rosario Palacios, Carlos Galera, Marta Fernández‐Fuertes, Alejandro González‐Serna, Itziar de Rojas, Agustı́n Ruiz, María Eugenia Sáez, Luís Miguel Real, Juan A. Pineda	1
7	Liver stiffness change with HCV cure in HIV-infected patients on non-nucleoside analogues 2021 ·Journal of Antimicrobial Chemotherapy ·Alejandro González‐Serna, Anaïs Corma‐Gómez, Francisco Téllez, (unknown), Antonio Rivero‐Juárez, Mario Frías, (unknown), Ignacio de los Santos, Dolores Merino, Luís Morano, Arkaitz Imaz, Carlos Galera, (unknown), Juan Macı́as, Juan A. Pineda	3
8	Kinetics of emergence of liver complications in hepatitis C virus infected patients and advanced fibrosis, with and without HIV-coinfection, after sustained virological response 2021 ·AIDS ·Anaïs Corma‐Gómez, Juan Macı́as, Francisco Téllez, Luís Morano, Antonio Rivero, (unknown), María Rios, (unknown), (unknown), Luís Miguel Real, Rosario Palacios, Ignacio de los Santos, Paloma Geijo, Arkaitz Imaz, Dolores Merino, Marı́a José Galindo, Sergio Reus, Miguel Ángel López‐Ruz, Carlos Galera, Juan A. Pineda	3
9	A Retrospective Analysis of Long-Term Changes of Inflammatory Biomarkers in Individuals on Suppressive Three-Drug or Two-Drug Antiretroviral Regimens 2021 ·SSRN Electronic Journal ·Sergio Serrano‐Villar, María Rosa López‐Huertas, (unknown), Carlos Galera, Javier Martínez‐Sanz, Elena Moreno, Alfonso Muriel, Félix Gutiérrez, Carmen Busca, Joaquín Portilla, Otilia Bisbal, José Antonio Iribarren, Francisco Tejerina, Ignacio de los Santos, Santiago Moreno	1
10	Baseline resistance-guided therapy does not enhance the response to interferon-free treatment of HCV infection in real life 2018 ·Scientific Reports ·Luís Miguel Real, Juan Macı́as, Ana Belén Pérez, Dolores Merino, Rafael Granados, Luís Morano, Marcial Delgado, María Rios, Carlos Galera, Miguel García Deltoro, Nicolás Merchante, Féderico García, Juan A. Pineda	3
11	Improvement of endothelial function after switching previously treated HIV‐infected patients to an NRTI‐sparing bitherapy with maraviroc 2014 ·Journal of the International AIDS Society ·Enrique Bernal, (unknown), (unknown), (unknown), (unknown), Carlos Galera, Ángeles Muñoz, (unknown), (unknown), (unknown), (unknown), Irene Marín, Alfredo Cano	6
12	Dual therapy with darunavir/r plus etravirine is safe and effective as switching therapy in antiretroviral experienced HIV‐patients. The BITER Study 2014 ·Journal of the International AIDS Society ·Joaquín Portilla, Piedad Arazo, (unknown), Laura Pérez‐Martínez, (unknown), Vicente Boix, (unknown), Vicente Navarro, (unknown), Sergio Reus, Carlos Galera, Enrique Bernal, Francisco Jover, Concha Amador, (unknown), Esperanza Merino, (unknown)	6
13	Clinical Utility of Maraviroc 2011 ·Clinical Drug Investigation ·(unknown), Joaquín Portilla, Federico Pulido, Rainel Sánchez-de la Rosa, Carlos Alonso‐Villaverde, Juan Berenguer, (unknown), Peré Domingo, Fernando Dronda, Carlos Galera, Félix Gutiérrez, José María Kindelán, Hernando Knobel, Manuel Leal, José López‐Aldeguer, Ana Mariño, Celia Miralles, José Moltó, Enrique Ortega, José A. Oteo	24
14	Osteonecrosis in Patients Infected With HIV 2006 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Félix Gutiérrez, Sergio Padilla, Mar Masiá, Juan Flores, Vicente Boix, Esperanza Merino, (unknown), Enrique Ortega, José López‐Aldeguer, Carlos Galera	33
15	Avascular necrosis of the bone in HIV-infected patients: incidence and associated factors 2002 ·AIDS ·Félix Gutiérrez, Sergio Padilla, Enrique Ortega, (unknown), Juan Flores, Carlos Galera, Esperanza Merino, Mar Masiá, P Roig, Vicente Boix, Joaquín Portilla, (unknown), (unknown), José I. López	29
16	Recurrent Kawasaki syndrome in an adult with HIV-1 infection. 1998 ·PubMed ·(unknown), C Redondo, Carlos Galera, Paloma Sánchez‐Pedreño, (unknown), (unknown)	12
17	[Hepatic toxicity caused by aceclofenac]. 1997 ·PubMed ·(unknown), (unknown), (unknown), Carlos Galera, (unknown)	3
18	Two cases of laryngeal leishmaniasis in patients infected with HIV 1994 ·European Journal of Clinical Microbiology & Infectious Diseases ·(unknown), José M. Peña, F J Barbado, J.J. González, C Redondo, Carlos Galera, Manuel Nistal, Juan José Vázquez	30

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact